Compositions and methods for molecular biology
The present invention provides materials and methods for the utilization of the specific interaction of replication termination sequences with their binding proteins in molecular biology applications.
1 . An isolated nucleic acid molecule engineered to comprise all or a portion of at least two Ter sites, wherein the nucleic acid comprises an origin of replication and the Ter sites are arranged with respect to the origin of replication such that the sequence between the two Ter sites is not replicated.
2 . The nucleic acid molecule of claim 1 , at least one Ter site is selected from a group consisting of TerA, TerB, TerC, TerD, TerE, TerF, TerG, Terh, TerI, and TerJ.
3 . The nucleic acid molecule of claim 1 , wherein the molecule comprises all or a portion of a TerB site.
4 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule is selected from a group consisting of plasmids, transposons, BACs, YACs, and phages.
5 . The nucleic acid molecule according to claim 1 , wherein the molecule is a linear molecule comprising all or a portion of a Ter site capable of being bound by a Ter-binding protein at each end.
6 . The molecule according to claim 1 , further comprising one or more sequences selected from a group consisting of recombination sequences, restriction enzyme recognition sequences, topoisomerase sites, promoters, enhancers, tag sequences and selectable marker sequences.
7 . The nucleic acid molecule according to claim 6 , wherein the recombination site is a site specific recombination site.
8 . The nucleic acid molecule according to claim 7 , wherein the recombination site is an att site.
9 . The nucleic acid molecule according to claim 8 , wherein the att site comprises a sequence of Table 3.
10 . A support comprising at least one oligonucleotide that comprises all or a portion of a Ter site.
11 . The support according to claim 10 , wherein the support is a non-biological material.
12 . The support according to claim 10 , wherein the oligonucleotide is capable of forming a stem-loop or hairpin.
13 . The support according to claim 10 , wherein a duplex portion of a stem-loop or hairpin comprises all or a portion of a Ter site.
14 . A support comprising all or a portion of a Ter-binding protein.
15 . The support according to claim 14 , wherein solid support is a non-biological material.
16 . The support according to claim 14 , wherein the Ter-binding protein comprises all or a portion of one or more sequences selected from the group of sequences of Tables 5-14.
17 . A method for directional cloning, comprising:
providing a nucleic acid molecule comprising one or more Ter sites or portions thereof;
providing a vector molecule comprising one or more Ter sites or portions thereof;
inserting the nucleic acid molecule into the vector molecule; and
selecting the vector molecule comprising the nucleic acid molecule in the desired orientation.
18 . The method according to claim 17 , wherein the selecting step comprises transfecting the vector molecule into a host cell, wherein the host cell expresses a Ter-binding protein.
19 . The method according to claim 18 , wherein the Ter-binding protein comprises all or a portion of one or more sequences selected from the group of sequences of Tables 5-14.
20 . The method according to claim 17 , wherein selecting comprises inhibiting replication of the vector molecule comprising the nucleic acid molecule in an undesired orientation.
21 . The method according to claim 17 , wherein the Ter site or sites in the nucleic acid molecule and the Ter site or sites in the vector are partial Ter sites.
22 . A method of cloning, comprising;
providing a linear vector comprising a portion of a Ter site on each end;
ligating a nucleic acid of interest with the vector to form a ligation mixture, wherein vectors that do not ligate with a nucleic acid reform a functional Ter site; and
introducing the ligation mixture into host cells, wherein host cells that receive a vector with a functional Ter site do not replicate the vector.
23 . The method of claim 22 , wherein the Ter site is selected from a group consisting of TerA, TerB, TerC, TerD, TerE, TerF, TerG, Terh, TerI, and TerJ.
24 . The method of claim 22 , wherein the Ter sites is a TerB site.
25 . The method of claim 22 , wherein the vector or the nucleic acid further comprise one or more sequences selected from a group consisting of recombination sequences, restriction enzyme recognition sequences, topoisomerase sites, promoters, enhancers, tag sequences and selectable marker sequences.
26 . The method of claim 25 , wherein the recombination site is a site specific recombination site.
27 . The method of claim 25 , wherein the recombination site is an att site.
28 . The method of claim 27 , wherein the att site comprises a sequence of Table 3.